Story perspectives

Samsung Biologics to Buy PolyPeptide for $1.8 B, Expands GLP-1 Reach

7/20/2026

Summary

Story summary

Samsung Biologics will acquire PolyPeptide Group for 2.7 trillion won ($1.8 billion) at a 40 % premium.
The transaction needs 66.7 % approval, has consent from Draupnir Holding B.V. (about 55 % of PolyPeptide), and will start a tender by late August, closing by December 2026.
The acquisition adds six peptide manufacturing sites in Europe, the United States and India, 1,500 staff, and expands Samsung Biologics into GLP-1 obesity and diabetes market projected $150 billion by 2035.

History

Historical Context

Roche’s $46 billion purchase of Genentech in 2009 marked its entry into large-scale biotech, following earlier moves such as the 1998 $11 billion Corange deal and the 2002 acquisition of Chugai. The 2024 $1.8 billion acquisition of PolyPeptide Group by Samsung Biologics reflects the same consolidation trend as firms chase the rapidly expanding GLP-1 market, prompting tighter regulatory scrutiny of cross-border biotech mergers.

1 of 2

Story summary

Samsung Biologics will acquire PolyPeptide Group for 2.7 trillion won ($1.8 billion) at a 40 % premium.
The transaction needs 66.7 % approval, has consent from Draupnir Holding B.V. (about 55 % of PolyPeptide), and will start a tender by late August, closing by December 2026.
The acquisition adds six peptide manufacturing sites in Europe, the United States and India, 1,500 staff, and expands Samsung Biologics into GLP-1 obesity and diabetes market projected $150 billion by 2035.

1 / 2